retatrutide clinical trial obesity trials Retatrutide approval: FDA status, clinical results, and when it could be available Eli Lilly Obesity Drug Market

Want to stop your GLP-1

Contrave The findings of the COR-BMOD trial found that, after 56 weeks, participants taking Contrave lost an average of 8.1% of their initial body weight, while the placebo group lost only 4.9%

Moderation matters more than usual

If hydration is hard, see electrolyte supplements while using GLP-1 medications

Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats

Have already discussed GLP-1 options with their primary care provider: If your physician has discussed GLP-1 medication as potentially appropriate for your situation and you are exploring compounded options specifically, a platform with clinician oversight and multiple partner pharmacies may warrant further evaluation